Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Open-label (Double Blind Among Rivaroxaban Groups in the Initial 3 Weeks), Parallel-group, Active-controlled Study of Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis Without Symptomatic Pulmonary Embolism

NCT01516840 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT01516840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01516840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Open-label (Double Blind Among Rivaroxaban Groups in the Initial 3 Weeks), Parallel-group, Active-controlled Study of Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis Without Symptomatic Pulmonary Embolism
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2012
Completion date
January 31, 2014
Enrollment
60 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

deep vein thrombosis